Advanced-design cross-linked binder enables high-performance silicon-based anodes through in-situ crosslinking based on sodium carboxymethyl cellulose and poly-lysine.

Practical employment of silicon (Si) electrodes in lithium-ion batteries (LIBs) is limited due to the severe volume changes suffered during charging-discharging process, causing serious capacity fading. Here, a composite polymer (CP-10) containing sodium carboxymethyl cellulose (CMC-Na) and poly-lysine (PL) is proposed for the binder of Si-based anodes, and a multifunctional strategy of "in-situ crosslinking" is achieved to alleviate the severe capacity degradation effectively. A cross-linked three-dimensional (3D) network is established through the strong hydrogen bonding interaction and reversible electrostatic interactions within CP-10, offering favorable mechanical tolerance for the extreme volume expansion of Si. Moreover, hydrogen bonding interaction along with ion-dipole interaction formed between CP-10 and Si surface enhance the bonding capability of Si-based anodes, promoting the maintenance of anodes' integrity. Consequently, over 800 cycles are achieved for the Si@CP-10 at 0.5C while maintaining a fixed discharge specific capacity of 1000 mAh g-1. Moreover, the Si/C@CP-10 can stably operate over 500 cycles with a capacity retention of 77.12 % at 1C. The prolonged cycling lifetime of Si/C and Si anodes suggests great potential for this strategy in promoting the implementation of high-capacity LIBs.

A biomass-rich, self-healable, and high-adhesive polymer binder for advanced lithium-sulfur batteries.

Although lithium-sulfur (Li-S) batteries have attracted a great deal of attention due to their ultrahigh energy density, the significant dissolution and shuttle of polysulfides, coupled with the unstable electrode structure, result in a substantial decline in capacity, thereby hindering their practical application in rapidly advancing energy storage systems. In this work, we prepare an environmentally friendly binder (LA-GA) that possesses self-healing abilities and high adhesion by combining dynamic disulfide (SS) bonds with abundant polar functional groups. Significantly, the self-healing capability provided by SS bonds facilitates the repair of cracks resulting from cathode volume expansion. Simultaneously, the polar functional groups (carboxyl and pyrogallol) not only enhance adhesion, preserving cathode integrity, but also effectively participate in lithium polysulfide adsorption, thereby inhibiting the shuttle effect. As a result, sulfur cathodes incorporating the LA-GA binder demonstrate favorable cycling stability, with a high capacity retention of 81.9 % when tested at 0.2C for 100 cycles. Additionally, the long-term cycling performance is satisfactory, showing a small capacity decline rate of 0.0469 % per cycle over 700 cycles at 1.0C.

In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets.

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, with F508del being the most prevalent mutation. The combination of CFTR modulators (potentiator and correctors) has provided benefit to CF patients carrying the F508del mutation; however, the safety and effectiveness of in utero combination modulator therapy remains unclear. We created a F508del ferret model to test whether ivacaftor/lumacaftor (VX-770/VX-809) therapy can rescue in utero and postnatal pathologies associated with CF. Using primary intestinal organoids and air-liquid interface cultures of airway epithelia, we demonstrate that the F508del mutation in ferret CFTR results in a severe folding and trafficking defect, which can be partially restored by treatment with CFTR modulators. In utero treatment of pregnant jills with ivacaftor/lumacaftor prevented meconium ileus at birth in F508del kits and sustained postnatal treatment of CF offspring improved survival and partially protected from pancreatic insufficiency. Withdrawal of ivacaftor/lumacaftor treatment from juvenile CF ferrets reestablished pancreatic and lung diseases, with altered pulmonary mechanics. These findings suggest that in utero intervention with a combination of CFTR modulators may provide therapeutic benefits to individuals with F508del. This CFTR-F508del ferret model may be useful for testing therapies using clinically translatable endpoints.